Mallinckrodt May Have to Pay More for Cadence
Cadence Pharmaceuticals agreed Tuesday to be bought out by Mallinckrodt for $1.3 billion, or a more than 27% premium to Monday's closing share price. Some investors may anticipate a sweetened offer.
Health and Healthcare
All Health and Healthcare Articles
Newest first · Page 296Gilead Going to $90, or $110
ThinkstockGilead Sciences Inc. (NASDAQ: GILD) is rising on Monday after two analysts made positive calls on the biotech giant. As a reminder, Gilead is now the world’s largest pure-play biotech as the market cap…
Eight Biotech Stocks Trading Near $5 With Huge Upside Potential
Here are the top biotech stocks to buy that are trading near the $5 dollar level. We have updated coverage on stocks we have reported on before, and added some top new names to…
Five Stocks That May Get a Huge Lift From the Affordable Care Act
In a new research report, J.P. Morgan analysts completed some exhaustive work and have narrowed down the list of stocks that should get the largest boost from the Affordable Care Act, or Obamacare as…
Teva Delivers on Earnings in Turnaround
Teva Pharmaceutical Industries is out with its fourth-quarter earnings report, and it looks as though the bad trends may be more and more in the past.
Merck Earnings Fail to Dazzle, but the Company’s Story Remains Strong
Before the markets opened Wednesday morning, drug giant Merck & Co. reported fourth-quarter and full-year 2013 results that failed to dazzle. But shares traded higher in the premarket session.
Despite Size, Gilead Keeps Growing and Growing
ThinkstockGilead Sciences Inc. (NASDAQ: GILD) is the biggest biotech company in America, and it is one of the top performers for 2013. Despite having a market cap of well over $100 billion now, this…
IBS Drug Success: The Fast and the Furiex
Usually when you see stocks double, it is based on a buyout or a major partnership development. That is not the case for Furiex Pharmaceuticals, which soared on news of positive top-line study results…
CytRx Flushed Its Shareholders, Even If It Needed the Capital
CytRx Corporation (NASDAQ: CYTR) saw its shares get punished on Friday for a secondary offering. Frankly, the pricing of the deal was such that it punished every single shareholder who was buying into the…
Three Biotech IPOs Hit on Friday, After Major IPO on Thursday
Six IPOs hit the market Friday , and three of them were biotechs. What stands out is that these emerging pharma deals came on the heels of a wildly successful biotech IPO on Thursday.
Why Caution Is Prevailing in Biotechs Into and After Earnings
Biogen Idec surprised investors Wednesday with weaker-than-expected guidance for 2014 earnings. Amgen beat estimates late Tuesday. Celgene and Gilead Sciences report earnings on Thursday.
UBS Says Buy Top Biotech Stocks in Front of Earnings for Big Upside
Like many firms on Wall Street, the biotechnology team at UBS thinks that most of the top mega-cap and large cap biotech stocks are poised to beat earnings estimates across the board. Investors who…
Amgen Nails Earnings, Guidance a Different Story
ThinkstockAmgen Inc. (NASDAQ: AMGN) is the second largest biotech player, and now we have seen its fourth-quarter earnings report. Earnings came in up 30% at $1.82 per share, and revenue was up 13% to…
Pfizer Delivers on Earnings, Sets 2014 Guidance
Pfizer has managed to handily beat consensus fourth-quarter earnings expectations, at least on the surface. It also offered guidance for 2014 in line with consensus estimates.
Analyst Team Sees Strong Biotech Buyout Market in 2014
Analysts at at Merrill Lynch see 2014 as a promising year for biotech mergers and acquisitions. A new research report shows which companies they believe will make acquisitions or which will be interested in…